Entera Bio Ltd

NASDAQ:ENTX   2:49:58 PM EDT
2.91
-0.01 (-0.34%)
Products, Earnings Announcements

Entera Bio Reports FDA Approval Of IND Application For EB613

Published: 12/10/2020 14:57 GMT
Entera Bio Ltd (ENTX) - Entera Bio Announces FDA Approval of Ind Application for Eb613 – an Oral Human Parathyroid Hormone (1-34) for the Treatment of Osteoporosis.
Entera Bio - Look Forward to Reporting Final Biomarker Data in Q1 of 2021 for Eb613.
Entera Bio Ltd - Look Forward to Reporting Final Bone Mineral Density Data From Eb613 Trial in Q2 of 2021.
Revenue is expected to be $0.09 Million
Adjusted EPS is expected to be -$0.12

Next Quarter Revenue Guidance is expected to be $0.09 Million
Next Quarter EPS Guidance is expected to be -$0.12

More details on our Analysts Page.